Last reviewed · How we verify
NCT05551507
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Phase 1, PHASE2 trial testing IN10018 in combination with PLD in Platinum-resistant Ovarian Cancer in 150 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | InxMed (Shanghai) Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 27 July 2020 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 7 locations across China |
Drugs / interventions tested
- IN10018 in combination with PLD — full drug profile →
Conditions studied
- Platinum-resistant Ovarian Cancer — all drugs for Platinum-resistant Ovarian Cancer →
Sponsor
InxMed (Shanghai) Co., Ltd. — full company profile →
Who can join
18 and older, female only, with Platinum-resistant Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05551507
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Platinum-resistant Ovarian Cancer
Currently open trials in the same condition.
- NCT07109414 — Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1) · Phase 2, PHASE3 · active not recruiting
- NCT06321484 — Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer · Phase 1 · recruiting
- NCT06515613 — A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors · Phase 1 · recruiting
- NCT04787289 — A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer · Phase 2 · recruiting
- NCT03949283 — Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer · Phase 3 · active not recruiting
Other InxMed (Shanghai) Co., Ltd. trials
Trials by the same sponsor.
- NCT07441174 — IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Soli · Phase 1, PHASE2 · recruiting
- NCT05982522 — IN10018 Combination Therapy in Previously-treated Solid Tumors · Phase 1, PHASE2 · withdrawn
- NCT06030258 — IN10018 Combination Therapy in Treatment-naïve ES-SCLC · Phase 1, PHASE2 · recruiting
- NCT05994131 — IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC · Phase 1, PHASE2 · recruiting
- NCT05827796 — IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05551507 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by InxMed (Shanghai) Co., Ltd.
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05551507.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing